Blue Capital Inc’s Gilead Sciences GILD Stock Holding History

Blue Capital Inc’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,464	Closed	-$273K	–	98
2025 Q2	$273K	Buy	+2,464	New	+$262K	0.19%	72

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Blue Capital Inc's GILD Position: Q3 2025 in Review

Blue Capital Inc sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 2,464 shares — an estimated $273K sold.

Blue Capital Inc first reported a position in GILD in Q2 2025 and held it in 1 quarter. The position peaked at $273K in Q2 2025. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

Blue Capital Inc reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
Blue Capital Inc sold 2,464 Gilead Sciences shares in Q3 2025, an estimated $273K.
Blue Capital Inc first reported a position in Gilead Sciences in Q2 2025 and held it in 1 quarter.
Blue Capital Inc's Gilead Sciences position peaked at $273K in Q2 2025.
2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Blue Capital Inc's 13F filing for Q3 2025, filed 14 Nov 2025.